Management Options for Dyspnoea in Palliative Care Patients

Dyspnoea is a common complaint in palliative care patients and requires appropriate management. Short-acting systemic opioids have been shown to be effective in alleviating dyspnoea in terminally ill patients, but caution should be exercised in patients with certain conditions. Heliox® and benzodiazepines may also be used in certain cases, but require expertise and careful consideration. Continuous non-invasive ventilatory support may be considered if other options fail, but requires adequate support. Nebulised opioids may also be a viable option depending on the underlying cause of dyspnoea. Treatment should be tailored to the individual patient’s needs.

Treatment Options for Malignant Dysphagia in Oesophageal Cancer Patients

Patients with oesophageal cancer often present with symptoms such as progressive dysphagia, weight loss, and anaemia. Unfortunately, these symptoms tend to appear late in the disease’s progression, making treatment more challenging. Oesophagectomy, the surgical removal of the oesophagus, is typically reserved for early-stage cancers that have not yet invaded surrounding tissues. Traditionally, malignant dysphagia was treated with repeated endoscopic dilatations. However, self-expanding metal stents (SEMS) are now the preferred treatment option for patients with malignant dysphagia.

While SEMS placement is generally safe and effective, there are some potential complications to be aware of. Early complications may include malposition, oesophageal perforation, bleeding, and stent migration. Late complications are more commonly related to eating, such as food bolus blockages or tumour overgrowth. If a food bolus blocks a stent, patients may be advised to consume a fizzy drink to help break it up. However, if this is unsuccessful, endoscopy may be required to dislodge the blockage.

In summary, SEMS placement is a safe and effective treatment option for patients with malignant dysphagia caused by oesophageal cancer. While there are potential complications to be aware of, these are generally manageable with prompt medical attention. Early diagnosis and treatment are crucial for improving outcomes in patients with oesophageal cancer.

Understanding Tumour Markers: Types and Associated Cancers

Tumour markers are compounds whose blood levels increase due to the presence of a particular malignant tumour. They are useful for diagnosis and detecting recurrence. However, they are not always specific, and different tumours may secrete the same marker. Here are some common tumour markers and the cancers they are associated with:

Alpha fetoprotein (AFP): Associated with liver and testicular cancers.

Prostate-specific antigen (PSA): Associated with prostate cancer.

Chemical nature Name Associated tumour
Enzyme PSA
NSE
LDH Prostate
Small cell lung cancer
Non-specific, mainly haematological
Hormone HCG
Calcitonin
Parathormone Testes
Medullary thyroid carcinoma
Parathyroid carcinoma
Immunoglobulin IgG, IgA, etc. Multiple myeloma
Glycoprotein AFP
CA-125
CA-19-9
CA-15-3
CEA Liver, also testes
Ovary
Pancreas
Breast
Colon, stomach

However, not all primary liver malignancies have AFP as a tumour marker. Certain types of liver malignancy, such as fibrolamellar carcinoma, hepatoblastoma, and hepatic angiosarcoma, do not secrete this protein. The first two usually occur in young persons. Hepatomas can occur de novo but are usually present because of an underlying disease such as hepatitis B infection (chronic) or cirrhosis of the liver. Alcoholism, aflatoxin, and obesity are also risk factors for hepatoma.

CA-125 is associated with ovarian cancer, CA-19-9 with pancreatic cancer, and HCG with testicular cancer. Understanding tumour markers and their associated cancers can aid in early detection and treatment.